[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495443":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":41,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":7,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Liposomal doxorubicin containing regimen","Liposomal doxorubicin hydrochloride (PLD) 30-40mg\u002Fm2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Xiaochen Wang, Dr.","CONTACT","+86 13958161286","wangxiaochen@zju.edu.cn",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Shizhen Zhang, Dr.","+86 15168338547","zhangshizhen@zju.edu.cn",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Second Affiliate Hospital of Zhejiang University","RECRUITING","Hangzhou","Zhejiang","310009","China","CN",{"type":33,"coordinates":34},"Point",[35,36],120.16142,30.29365,{"lat":36,"lon":35},[39,40],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100495443","observational-of-adjuvant-treatment-of-breast-cancer-with-liposomal-doxorubicin-regimen-100495443",false,"NCT05731258","Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen","Clinical Observational Study of Postoperative Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen","Inclusion Criteria:\n\n1. Female, aged 18-75 years;\n2. Primary breast cancer diagnosed histopathologically;\n3. Adjuvant chemotherapy regimens include liposomal doxorubicin;\n4. ECoG PS score: 0-1 points;\n5. Left ventricular ejection fraction (LVEF) ≥ 55%;\n6. Estimated survival ≥ 6 months;\n7. Major organ function is normal, i.e. meets the following criteria:\n\n   ① And white blood cells ≥ 4.0 × 10 9 \u002F L, neutrophil count (ANC) ≥ 1.5 × 10 9 \u002FL；② Platelets ≥ 100 × 10 9 \u002FL；③ And hemoglobin ≥ 10 g \u002F dl; ④ Serum creatinine ≤ 1.5 × ⑤ the upper limit of normal (ULN) Mmol \u002F L and aspartate transaminase (AST) ≤ 2.5\n\n   × ULN；⑥ Alanine transaminase (ALT) ≤ 2.5 × ULN；⑦ Total bilirubin ≤ 1.5 × ULN；⑧ Serum creatinine ≤ 1.5 × ULN；\n8. Subjects voluntarily join this study, sign the informed consent form, have good compliance and cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Pregnant, lactating patients;\n2. Breast cancer has been found to have distant metastasis;\n3. Those with peripheral nervous system disorders caused by the disease or with a history of significant mental disorders and central nervous system disorders;\n4. Those with severe infection or active peptic ulcer requiring treatment;\n5. Allergic to chemotherapy drugs;\n6. Cancer free period less than 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the cervix;\n7. Severe liver disease (e.g., cirrhosis, etc.), renal disease, respiratory disease, or uncontrolled diabetes;\n8. Patients who are participating in other clinical trials or within a month.","FEMALE","18 Years","75 Years",{"count":54,"type":55},150,"ESTIMATED","OBSERVATIONAL","The goal of this observational study aims to observe and evaluate the efficacy and safety of a liposomal doxorubicin containing regimen in the postoperative adjuvant treatment of breast cancer patients.",[59,60,61,62,63],"Breast Cancer","Liposomal Doxorubicin","Efficacy","Safety","Postoperative Adjuvant Treatment","2023-02-07",{"date":66,"type":67},"2023-02-16","ACTUAL",{"date":69,"type":67},"2022-05-01",{"date":71,"type":55},"2032-10",{"name":5,"class":6},1]